178 related articles for article (PubMed ID: 32720232)
21. Machine learning models reveal neurocognitive impairment type and prevalence are associated with distinct variables in HIV/AIDS.
Tu W; Chen PA; Koenig N; Gomez D; Fujiwara E; Gill MJ; Kong L; Power C
J Neurovirol; 2020 Feb; 26(1):41-51. PubMed ID: 31520320
[TBL] [Abstract][Full Text] [Related]
22. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment.
Tozzi V; Balestra P; Galgani S; Narciso P; Ferri F; Sebastiani G; D'Amato C; Affricano C; Pigorini F; Pau FM; De Felici A; Benedetto A
AIDS; 1999 Oct; 13(14):1889-97. PubMed ID: 10513647
[TBL] [Abstract][Full Text] [Related]
23. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
[TBL] [Abstract][Full Text] [Related]
25. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
[TBL] [Abstract][Full Text] [Related]
26. Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations.
Oliveira MF; Chaillon A; Nakazawa M; Vargas M; Letendre SL; Strain MC; Ellis RJ; Morris S; Little SJ; Smith DM; Gianella S
PLoS Pathog; 2017 Jan; 13(1):e1006112. PubMed ID: 28046096
[TBL] [Abstract][Full Text] [Related]
27. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
[TBL] [Abstract][Full Text] [Related]
28. Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
Braun DL; Scheier T; Ledermann U; Flepp M; Metzner KJ; Böni J; Günthard HF
Viruses; 2020 Nov; 12(11):. PubMed ID: 33228206
[TBL] [Abstract][Full Text] [Related]
29. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
[TBL] [Abstract][Full Text] [Related]
30. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
31. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.
Rasmussen TA; McMahon JH; Chang JJ; Audsley J; Rhodes A; Tennakoon S; Dantanarayana A; Spelman T; Schmidt T; Kent SJ; Morcilla V; Palmer S; Elliott JH; Lewin SR
Lancet HIV; 2018 May; 5(5):e221-e230. PubMed ID: 29643011
[TBL] [Abstract][Full Text] [Related]
32. Simplification of combination antiretroviral therapy (cART) and the brain-a real-life experience.
Arendt G; Schlonies S; Orhan E; Stüve O
J Neurovirol; 2019 Apr; 25(2):174-182. PubMed ID: 30628025
[TBL] [Abstract][Full Text] [Related]
33. HIV-associated neurocognitive disorders and central nervous system drug penetration: what next?
Marra CM
Antivir Ther; 2015; 20(4):365-7. PubMed ID: 25781980
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
35. Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir.
Keegan MR; Winston A; Higgs C; Fuchs D; Boasso A; Nelson M
J Neurovirol; 2019 Feb; 25(1):85-90. PubMed ID: 30478800
[TBL] [Abstract][Full Text] [Related]
36. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
Demarest J; Underwood M; St Clair M; Dorey D; Brown D; Zolopa A
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):343-346. PubMed ID: 29444582
[TBL] [Abstract][Full Text] [Related]
37. Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings.
Cattaneo D; Sollima S; Meraviglia P; Milazzo L; Minisci D; Fusi M; Filice C; Gervasoni C
Drugs R D; 2020 Jun; 20(2):155-160. PubMed ID: 32189238
[TBL] [Abstract][Full Text] [Related]
38. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
39. Determinants of Survival of HIV Patients Receiving Dolutegravir: A Prospective Cohort Study in Conflict-Affected Bunia, Democratic Republic of Congo.
Buju RT; Akilimali PZ; Tran NT; Kamangu EN; Mesia GK; Kayembe JMN; Situakibanza HN
Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011850
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.
Nasreddine R; Florence E; Vandercam B; Moutschen M; Goffard JC; De Munter P; Delforge M; Marinus W; De Wit S;
AIDS; 2020 Jul; 34(8):1151-1159. PubMed ID: 32287063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
